| Patent application number | Description | Published |
|---|
| 20080269103 | Diagnostic and Therapeutic Use of the Kcne4 Gene and Protein for Alzheimer's Disease - The present invention discloses the differential expression of the gene coding for KCNE4 protein in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject, is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the KCNE4 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed. | 10-30-2008 |
| 20080301821 | Diagnostic and Therapeutic use of a Plasma Membrane Atpase - The present invention provides a protein encoded by the ATP2B gene and discloses the differential expression of the gene coding for ATP2B proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the ATP2B gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed. | 12-04-2008 |
| 20090047274 | Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases - The present invention discloses a dysregulation of the CDC2L6 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the CDC2L6 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 02-19-2009 |
| 20090133135 | Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases - The present invention discloses a dysregulation of the SLC39A12 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A12 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 05-21-2009 |
| 20090136504 | Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases - The present invention discloses a dysregulation of a PRKX gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using a PRKX gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 05-28-2009 |
| 20090172827 | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases - The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 07-02-2009 |
| 20090255003 | Diagnostic and therapeutic target SLC39A11 proteins for neurodegenerative diseases - The present invention discloses a dysregulation of the SLC39A11 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A11 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 10-08-2009 |
| 20100008921 | Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases - The present invention discloses a dysregulation of the ADARB2 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the ADARB2 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 01-14-2010 |
| 20100261182 | PPM1E PROTEINS AND NUCLEIC ACIDS AS TARGETS FOR NEURODEGENERATIVE DISEASES | 10-14-2010 |
| 20110010780 | KCNN3 AS DIAGNOSTIC AND THERAPEUTIC TARGET FOR NEURODEGENERATIVE DISEASES - The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 01-13-2011 |
